Drugs / amoxycillin-clavulanic acid
amoxycillin-clavulanic acid
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT03459599 Comparator | Oct 2016 → Mar 2017 | endometritis | Sarawak General Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amoxycillin + Clavulanic acid | “None of the authors have received any form of honoraria, funding, grant, employment or have financial interest in the manufacturer of Co-Amoxiclav™ (Amoxycillin + Clavulanic...” PMID 31296180 ↗ Jul 20191“Three hospitals where the current protocol was to administer prophylactic amoxycillin-clavulanic acid served as the sites of recruitment.” PMID 31296180 ↗ Jul 2019 |
| Known as | Amox-clav | “Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week” NCT03459599 ↗ |
| Known as | Co-Amoxiclav | “None of the authors have received any form of honoraria, funding, grant, employment or have financial interest in the manufacturer of Co-Amoxiclav™ (Amoxycillin + Clavulanic...” PMID 31296180 ↗ Jul 2019 |